How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/endoscopic-photodynamic-ablation-adjunct-for-cancer-or-high-grade-dysplasia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	First approval
Photofrin	porfimer	Concordia Labs Inc	Photoactivated Radical Generator	1995-01-01
Photofrin	Photofrin	Samsung Medical Center
Photodyn	Hematoporphyrin	Hepatopancreatobiliary Surgery Institute of Gansu Province	hematoporphyrin

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Concordia Labs Inc · 1 drug in Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia
Hepatopancreatobiliary Surgery Institute of Gansu Province · 1 drug in Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia
Samsung Medical Center · 1 drug in Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia:

Cite this brief

Drug Landscape (2026). Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/endoscopic-photodynamic-ablation-adjunct-for-cancer-or-high-grade-dysplasia. Accessed 2026-06-10.

Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing